Initial results found that among 1060 participants in 30 countries, the pembrolizumab plus CCRT group conferred better PFS at 24 months than the placebo plus CCRT group (68% vs 57%; hazard ratio [HR], ...
Northwestern Medicine investigators have identified novel mechanisms regulating the development of the spinal column during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback